Filing Flows › Health Care › Indivior Pharmaceuticals (INDV)
Indivior Pharmaceuticals (INDV) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 29, 2026 · Indivior Pharmaceuticals (INDV) Q3 2026 earnings results →
Q3 2026 Revenue up 13% year over year to $356M · 38¢ of every $1 of revenue kept as net profit · operating margin 50.6%
Indivior Pharmaceuticals made $356M in Q3 2026 (+13% Y/Y). Operating margin 50.6%, net earnings $137M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 29, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $356.0M in Q3 2026, up 13% year over year and up 4% from the previous quarter.
Gross margin was 85.7%, up 12.4 points from Q3 2025. Operating profit was $180.0M, a 50.6% margin (up 36.9 points year over year). Of the extra revenue versus Q3 2025, 326% reached operating profit, above the 14% margin then. Operating expenses fell 33% while revenue rose 13%. Net earnings were $137.0M, up 226% year over year. The effective tax rate was 24.7%.
Operating cash flow was $97.0M, 71% of net earnings. Non-cash charges added back $1.0M of depreciation and amortization and $8.0M of share-based compensation. Working capital and other items used $49.0M. Capital expenditures of $14.0M left free cash flow of $83.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 29, 2026 | $356M | +13% | 50.6% | $137M | $97.0M |
| Q2 2026 | 10-Q | Aug 3, 2026 | $343M | +14% | 46.6% | $122M | $229M |
| Q1 2026 | 10-Q | Apr 30, 2026 | $317M | +19% | 43.2% | $89.0M | −$9.0M |
| Q4 2025 | 10-K | Feb 26, 2026 | $358M | +20% | 22.6% | $102M | −$221M |
| Q3 2025 | 10-Q | Oct 30, 2025 | $314M | +2% | 13.7% | $42.0M | −$39.0M |
| Q2 2025 | 10-Q | Jul 31, 2025 | $302M | +1% | 23.8% | $18.0M | $158M |
| Q1 2025 | 10-Q | May 1, 2025 | $266M | -6% | 24.8% | $47.0M | $75.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Indivior Pharmaceuticals
Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease. For more than 25 years, Indivior has led innovation in addiction medicine, developing differentiated therapeutic solutions that support long-term patient recovery, expand access to care, and drive sustainable value for patients, healthcare systems and stockholders.
In its own words, from its 10-K, filed Feb 26, 2026.
Indivior Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +13% against the peers' median +10%. Operating margin: 50.6% against the peers' median 30.7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| INDV Indivior Pharmaceuticals | Q3 2026 | $356M | +13% | 50.6% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Indivior Pharmaceuticals 10-Q on SEC EDGAR · CIK 1625297 · Pharmaceutical Preparations
13F: who owns INDV and who is buying
More on INDV
- How Indivior Pharmaceuticals makes money: revenue by segment
- Indivior Pharmaceuticals next earnings date and what analysts expect
- Indivior Pharmaceuticals stock forecast, price target and fair value
- Who owns Indivior Pharmaceuticals stock: holders, funds and Congress trades
- Is Indivior Pharmaceuticals a takeover target? LBO and rumors
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Indivior Pharmaceuticals gross margin by quarter
- Indivior Pharmaceuticals operating margin by quarter
- Indivior Pharmaceuticals net income by quarter
- Indivior Pharmaceuticals free cash flow by quarter
- Indivior Pharmaceuticals R&D spending by quarter
- Indivior Pharmaceuticals capital expenditures by quarter
Compare INDV with
- Indivior Pharmaceuticals vs Phibro Animal Health (INDV vs PAHC)
- Indivior Pharmaceuticals vs Sarepta Therapeutics (INDV vs SRPT)
- Indivior Pharmaceuticals vs PTC Therapeutics (INDV vs PTCT)
- Indivior Pharmaceuticals vs BridgeBio Pharma (INDV vs BBIO)
- Indivior Pharmaceuticals vs Acadia Pharmaceuticals (INDV vs ACAD)